½ÃÀ庸°í¼­
»óǰÄÚµå
1347826

ºñÀεΠ½º¿Ò ½ÃÀå - ¼ºÀå, ÇâÈÄ Àü¸Á, °æÀï ºÐ¼®(2023-2031³â)

Nasopharyngeal Swabs Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Acute Market Reports | ÆäÀÌÁö Á¤º¸: ¿µ¹® 115 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ºñÀεΠ½º¿Ò ½ÃÀåÀº ƯÈ÷ COVID-19 ÆÒµ¥¹Í ±â°£ µ¿¾È Áø´Ü °Ë»ç ¼ö¿ä Áõ°¡¿¡ ÈûÀÔ¾î 2023-2031³â ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ 2.5%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºñÀεΠ½º¿Ò´Â È£Èí±â °Ëü äÃë¿¡ ³Î¸® »ç¿ëµÇ¾î ÀÎÇ÷翣ÀÚ, È£Èí±â ¼¼Æ÷À¶ÇÕ ¹ÙÀÌ·¯½º(RSV), COVID-19ÀÇ ¿øÀÎ ¹ÙÀÌ·¯½ºÀÎ SARS-CoV-2¿Í °°Àº °¨¿°¼º ÁúȯÀ» °ËÃâÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â Áúº´ Á¶±â ¹ß°ßÀÇ Á߿伺¿¡ ´ëÇÑ ÀÇ·á Àü¹®°¡¿Í ÀÏ¹Ý ´ëÁßÀÇ ÀνÄÀÌ ³ô¾ÆÁø °ÍÀÔ´Ï´Ù. ºñÀεΠ½º¿Ò´Â ºñħ½ÀÀûÀÌ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ¸·Î È£Èí±â °Ëü¸¦ äÃëÇÒ ¼ö Àֱ⠶§¹®¿¡ Áø´Ü °Ë»ç¿¡ ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇöÀå °Ë»ç ½Ã¼³ÀÇ º¸±ÞÀº ºñÀεΠ½º¿Ò¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¸ÅÃâÀº ÁÖ·Î COVID-19 °Ë»ç¿¡ ´ëÇÑ Àü·Ê ¾ø´Â ¼ö¿ä·Î ÀÎÇØ Å©°Ô ±ÞÁõÇß½À´Ï´Ù. Àü ¼¼°è Á¤ºÎ¿Í ÀÇ·á ±â°üÀÌ Áø´Ü °Ë»ç ÀÎÇÁ¶ó¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϸ鼭 ºñÀεΠ½º¿ÒÀÇ Ã¤ÅÃÀÌ ±ÞÁõÇß½À´Ï´Ù. ¶ÇÇÑ, Áö¼ÓÀûÀÎ R&D Ȱµ¿À¸·Î ȯÀÚÀÇ ÆíÀǼº°ú °Ëü äÃë È¿À²À» ³ôÀÌ´Â Çõ½ÅÀûÀÎ ¸éºÀ µðÀÚÀÎÀÌ µµÀÔµÇ¾î ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÇÏÁö¸¸ ½ÃÀå¿¡´Â µµÀü°úÁ¦°¡ ¾ø´Â °ÍÀº ¾Æ´Õ´Ï´Ù. ÀÇ·á±â±â¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç°ú Áö¿ªº°·Î »óÀÌÇÑ »óȯ Á¤Ã¥Àº ºñÀεΠ¸éºÀÀÇ ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ Å¸¾× ±â¹Ý °Ë»ç¿Í °°Àº ´ëü °Ëü äÃë ¹æ¹ýÀÇ ÃâÇöÀº ½ÃÀå È®´ë¿¡ ÀáÀçÀûÀÎ À§ÇùÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ Áø´Ü °Ë»ç ¼ö¿ä Áõ°¡

COVID-19 ÆÒµ¥¹ÍÀº ºñÀεΠ½º¿Ò ½ÃÀåÀÇ Å« ÃËÁøÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ·¯½º¸¦ ½Äº°Çϰí È®»êÀ» ¾ïÁ¦Çϱâ À§ÇØ ±¤¹üÀ§ÇÑ Áø´Ü °Ë»ç°¡ ÇÊ¿äÇØÁö¸é¼­ ºñÀεΠ½º¿Ò¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇß½À´Ï´Ù. Àü ¼¼°è Á¤ºÎ¿Í ÀÇ·á ±â°üÀÌ °Ë»ç ÀÎÇÁ¶ó¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϸ鼭 ½ÃÀå ¼ºÀå¿¡ ±â¿©Çß½À´Ï´Ù. COVID-19 »çÅ·ΠÀÎÇØ ºñÀεΠ¼¼Ã´¾×ÀÌ ºÎÁ·ÇÏ´Ù´Â º¸°í°¡ ¿©·¯ ±¹°¡¿¡¼­ ³ª¿Ô½À´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â ÃÊ ¹Ì±¹Àº °ø±Þ ºÎÁ·¿¡ Á÷¸éÇÏ¿© Á¤ºÎ°¡ °Ë»ç ½Ã¼³¿¡ ¸éºÀÀ» ´õ ¸¹ÀÌ »ý»êÇÏ°í ¹èÆ÷ÇÏ´Â Á¶Ä¡¸¦ ÃëÇß½À´Ï´Ù. ´Ù¸¥ Áö¿ª¿¡¼­µµ ºñ½ÁÇÑ º¸°í°¡ ÀÖ¾î Àü¿°º´ ±â°£ µ¿¾È ºñÀεΠ½º¿Ò¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

ȯÀÚÀÇ Æí¾ÈÇÔ°ú °Ëü äÃë È¿À²À» ³ôÀÌ´Â ¸éºÀ µðÀÚÀÎÀÇ ¹ßÀü

ÇコÄÉ¾î ¾÷°èÀÇ Áö¼ÓÀûÀÎ ¿¬±¸ °³¹ß ³ë·ÂÀ¸·Î »óÀεΠ¸éºÀÀÇ µðÀÚÀÎÀÌ Å©°Ô °³¼±µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº °Ëü äÃë Áß È¯ÀÚÀÇ Æí¾ÈÇÔÀ» ³ôÀ̰í, ½Ã¼úÀÇ Ä§½À¼ºÀ» ÁÙÀ̰í, °Ëü äÃë È¿À²À» Çâ»ó½ÃŰ´Â µ¥ ÁßÁ¡À» µÓ´Ï´Ù. ÀÇÇÐ Àú³Î¿¡ ½Ç¸° ¿¬±¸´Â ¸éºÀ µðÀÚÀÎÀÇ ´Ù¾çÇÑ ¹ßÀüÀ» º¸°íÇϰí ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â »ùÇÃÀ» äÃëÇÒ ¶§ ȯÀÚ¿¡°Ô ºÒÆíÇÔÀ» ÁÖÁö ¾Ê´Â À¯¿¬ÇÏ°í ºÎµå·´°í ÀÛÀº Å©±âÀÇ ¸éºÀ °³¹ßÀÌ Æ÷ÇԵ˴ϴÙ. ¿¬±¸ ³í¹®Àº ¶ÇÇÑ Á¤È®ÇÑ Áø´Ü °Ë»ç¿¡ ÇÊ¿äÇÑ ÃæºÐÇÑ »ùÇÃÀ» äÃëÇϱâ À§ÇØ »õ·Î¿î ¸éºÀ µðÀÚÀÎÀÇ È¿°ú¸¦ °­Á¶ÇÏ°í ¸éºÀ ±â¼úÀÇ Áö¼ÓÀûÀÎ °³¼±ÀÇ Á߿伺À» °­Á¶ÇÕ´Ï´Ù.

Áúº´ÀÇ Á¶±â ¹ß°ß ¹× ÇöÀå °Ë»ç ½Ã¼³¿¡ ´ëÇÑ ÀÎ½Ä Á¦°í

Áúº´ Á¶±â ¹ß°ßÀÇ Á߿伺¿¡ ´ëÇÑ ÀÇ·á Àü¹®°¡¿Í ÀÏ¹Ý ´ëÁßÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ºñÀεΠ½º¿ÒÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÇöÀå °Ë»ç ½Ã¼³ÀÌ ³Î¸® º¸±ÞµÇ¸é¼­ °³ÀεéÀÌ ½Å¼ÓÇÏ°Ô °Ë»ç¸¦ ¹Þ°í ºü¸¥ °á°ú¸¦ ¹ÞÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. °øÁß º¸°Ç Ä·ÆäÀÎ, ¾ð·Ð º¸µµ ¹× ±³À° ÀÌ´Ï¼ÅÆ¼ºê´Â Áúº´ Á¶±â ¹ß°ßÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ±× °á°ú, »ç¶÷µéÀº Áø´Ü °Ë»ç¸¦ ¹Þ±â¸¦ ¿øÇÏ°Ô µÇ¾ú°í, ¸¹Àº °æ¿ì ºñÀεΠ¼¼Ã´¾×À» Æ÷ÇÔÇÑ Áø´Ü °Ë»ç¸¦ ¹ÞÀ¸·Á´Â °æÇâÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áø·á¼Ò, ¾à±¹ ¹× Ä¿¹Â´ÏƼ ¼¾ÅÍ¿¡ ÇöÀå °Ë»ç ½Ã¼³À» ¼³Ä¡ÇÏ¿© °Ë»ç¸¦ ´õ °¡±õ°í Æí¸®ÇÏ°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÊ¿¡ µû¶ó ºñÀεΠ¼¼Ã´¾×¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÀÇ·á±â±â¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä±¸ »çÇ×

ºñÀεΠ¸éºÀ ½ÃÀåÀº ¸éºÀÀ» Æ÷ÇÔÇÑ ÀÇ·á±â±â¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀ¸·Î ÀÎÇØ Å« Á¦¾à ¿äÀο¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. °¢ Áö¿ªÀÇ ±ÔÁ¦ ´ç±¹Àº ¸éºÀÀÇ ½ÃÀå ÁøÀÔÀ» Çã¿ëÇϱâ Àü¿¡ ¾ö°ÝÇÑ Å×½ºÆ®, ¾ÈÀü¼º Æò°¡ ¹× ǰÁú °ü¸® Á¶Ä¡¸¦ Àǹ«È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ä±¸ »çÇ×Àº Á¾Á¾ ½ÂÀÎ ±â°£À» ¿¬ÀåÇϰí Á¦Á¶¾÷üÀÇ ºñ¿ë Áõ°¡·Î À̾îÁý´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ½ÄǰÀǾ౹(FDA)Àº ¸éºÀ Á¦Á¶¾÷ü°¡ Á¦Ç°À» ÆÇ¸ÅÇϱâ Àü¿¡ ½ÃÆÇ Àü ÅëÁö ÀýÂ÷(510(k))¸¦ ÁؼöÇϰųª ½ÃÆÇ Àü ½ÂÀÎ(PMA)À» ¹Þµµ·Ï ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î À¯·´¿¬ÇÕ(EU)ÀÇ CE ¸¶Å· ÀýÂ÷´Â ÀÇ·á±â±â¿¡ ´ëÇÑ ÀûÇÕ¼º Æò°¡¿Í Çʼö °Ç°­ ¹× ¾ÈÀü ¿ä°ÇÀ» ÃæÁ·ÇØ¾ß ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±î´Ù·Î¿î ±ÔÁ¦ À庮Àº Á¦Ç° Ãâ½Ã¸¦ Áö¿¬½ÃŰ°Å³ª Áß¼Ò±â¾÷ÀÇ ºñÀεΠ¼¼Ã´Á¦ ½ÃÀå ÁøÀÔÀ» ¹æÇØÇÏ¿© Àüü ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ±× °á°ú, ±â¾÷µéÀº ±ÔÁ¦ °¡À̵å¶óÀÎÀ» ÁؼöÇϱâ À§ÇØ ¸¹Àº ½Ã°£°ú ÀÚ¿øÀ» ÅõÀÚÇØ¾ß Çϸç, ÀÌ´Â Çõ½ÅÀ» ¹æÇØÇÏ°í ½ÃÀå È®´ë¸¦ Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. Àú¸íÇÑ ÀÇÇÐ Àú³Î¿¡ °ÔÀçµÈ ¿¬±¸ ³í¹®°ú ±â»ç´Â ÀÇ·á±â±â Á¦Á¶¾÷ü°¡ ºñÀεΠ¼¼Ã´¾×¿¡ ´ëÇÑ ±ÔÁ¦ ¿ä°ÇÀ» ÃæÁ·Çϱâ À§ÇØ Á÷¸éÇÑ °úÁ¦¿¡ ´ëÇØ ³íÀÇÇϰí ÀÖ½À´Ï´Ù. ÀÌ º¸°í¼­µéÀº ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» ¹Þ±â À§ÇØ ÇÊ¿äÇÑ º¹ÀâÇÑ ÇÁ·Î¼¼½º¿Í ¹æ´ëÇÑ ¹®¼­¿¡ ´ëÇØ ÀÚ¼¼È÷ ¼³¸íÇÕ´Ï´Ù. ¶ÇÇÑ, »ç·Ê ¿¬±¸¿¡¼­´Â ±î´Ù·Î¿î ±ÔÁ¦ ¿ä±¸ »çÇ×À¸·Î ÀÎÇØ ºñÀεΠ¼¼Ã´Á¦ÀÇ ½ÃÀå Ãâ½Ã°¡ Áö¿¬µÇ°Å³ª Àå¾Ö¹°¿¡ Á÷¸éÇÑ »ç·Êµµ ¼Ò°³µË´Ï´Ù.

Æû ÆÁ ¸éºÀÀº ¿¹Ãø ±â°£ µ¿¾È ºñÁö´Ï½º ±âȸ¸¦ Á¦°ø

½ÃÁß¿¡¼­ ÆÇ¸ÅµÇ´Â ´Ù¾çÇÑ Á¾·ùÀÇ ºñÀεΠ¸éºÀ Áß Æû ÆÁ ¸éºÀÀº 2023³âºÎÅÍ 2031³â±îÁö ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Æû ÆÁ ¸éºÀÀº ½Ã·á äÃëÀÇ ¿ì¼öÇÑ ¼º´É°ú ȯÀÚÀÇ Æí¾ÈÇÔÀ¸·Î ÀÎÇØ Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù. ºÎµå·´°í À¯¿¬ÇÑ Æû ¼ÒÀç´Â ½Ã·á äÃë ½Ã ºñ°­ ³» ºÒÆíÇÔÀ̳ª ºÎ»óÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÏ¿© ÀÇ·á Àü¹®°¡¿Í ȯÀÚ ¸ðµÎ¿¡°Ô ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Æû ÆÁ ¸éºÀÀº Á¤È®ÇÑ Áø´Ü °Ë»ç¸¦ À§ÇØ ÃæºÐÇÑ »ùÇÃÀ» äÃëÇÏ´Â µ¥ ÀÖ¾î ³ôÀº È¿À²¼ºÀÌ ÀÔÁõµÇ¾î COVID-19¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ È£Èí±â °¨¿° Áúȯ¿¡ ´ëÇÑ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±× °á°ú, COVID-19 »çÅ·ΠÀÎÇØ ³¡ÀÌ »ÏÁ·ÇÑ ¸éºÀ¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇØ ¸ÅÃâ Áõ°¡¿¡ Å« ±â¿©¸¦ Çß½À´Ï´Ù. ¹Ý¸é ºÎÁ÷Æ÷ ¸éºÀÀÇ CAGR°ú ¼öÀÍÀº »ó´ëÀûÀ¸·Î ³·½À´Ï´Ù. ºÎÁ÷Æ÷ ¸éºÀÀº ³Î¸® »ç¿ëµÇ°í ½±°Ô ±¸ÇÒ ¼ö ÀÖÁö¸¸, °Åǰ ¸éºÀ¿¡ ºñÇØ »ç¿ë°¨À̳ª È¿À²¼ºÀÌ ¶³¾îÁø´Ù°í »ý°¢Çϱ⠽±½À´Ï´Ù. ºÎÁ÷Æ÷ ¸éºÀº¸´Ù ÆûÆÁ ¸éºÀÀ» ¼±È£ÇÏ´Â °ÍÀº ºñÀεΠ½º¿Ò ½ÃÀå¿¡¼­ÀÇ ³ôÀº äÅ÷ü°ú ¼öÀÍ¿¡¼­ ¾Ë ¼ö ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, '±âŸ' Ä«Å×°í¸®¿¡´Â Æû ÆÁ°ú ºÎÁ÷Æ÷ ÀÌ¿ÜÀÇ ´Ù¾çÇÑ À¯ÇüÀÇ ºñÀεΠ½º¿Ò°¡ Æ÷ÇÔµÇÁö¸¸, ½ÃÀå Á¡À¯À²Àº ÀÛ½À´Ï´Ù. ÀÌ ºÎ¹®Àº Æ´»õ ½ÃÀåÀ» Á¦°øÇÏÁö¸¸, ÆûÆÁ ¸éºÀÀÇ ¿ì¼öÇÑ ¼º´É°ú ¼ö¿ë¼º¿¡ ¸Â¼­¾ß ÇÏ´Â °úÁ¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î, Æû ÆÁ ¸éºÀÀº ºñÀεΠ½º¿Ò ½ÃÀå¿¡¼­ ¶Ñ·ÇÇÑ ¼±µÎ ÁÖÀÚ·Î ºÎ»óÇϰí ÀÖÀ¸¸ç, ¶Ù¾î³­ È¿À²¼º, ȯÀÚ ÆíÀǼº ¹× COVID-19 ´ëÀ¯Çà ±â°£ µ¿¾È ¼ö¿ä Áõ°¡·Î ÀÎÇØ °¡Àå ³ôÀº CAGRÀ» °æÇèÇÏ°í °¡Àå ³ôÀº ¼öÀÍÀ» âÃâÇϰí ÀÖ½À´Ï´Ù.

º´¿øÀÌ ¿©ÀüÈ÷ ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚ

ºñÀεΠ½º¿Ò ½ÃÀåÀÇ ´Ù¾çÇÑ ÃÖÁ¾»ç¿ëÀÚ ºÎ¹® Áß º´¿øÀº 2023³âºÎÅÍ 2031³â±îÁö ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» º¸À̸ç 2022³â ¼öÀÍÀÌ ¿¹»óµË´Ï´Ù. º´¿øÀº È£Èí±â °¨¿°ÀÇ Áø´Ü ¹× Ä¡·á¿¡ Áß¿äÇÑ ¿ªÇÒÀ»Çϱ⠶§¹®¿¡ ºñÀεΠ½º¿ÒÀÇ ÁÖ¿ä ¼ÒºñÀÚÀ̸ç, COVID-19¿Í °°Àº Àü¿°º´ÀÌ ±ÞÁõÇÔ¿¡ µû¶ó ºñÀεΠ½º¿Ò¿¡ ´ëÇÑ º´¿øÀÇ ¼ö¿ä°¡ ±ÞÁõÇÏ¿© ³ôÀº ¼öÀÍ¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ º´¿øÀº Àß ±¸ÃàµÈ ÀÇ·á ÀÎÇÁ¶ó¿Í °Ë»ç½ÇÀ» °®Ãß°í ÀÖ¾î È¿À²ÀûÀÌ°í ´ë±Ô¸ð °Ë»ç¸¦ ÇÒ ¼ö ÀÖ¾î ºñÀεΠ½º¿Ò¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. Ŭ¸®´Ðµµ Áß¿äÇÑ ¼ÒºñÀÚÀÌÁö¸¸ CAGR°ú ¼öÀÍÀº »ó´ëÀûÀ¸·Î ³·½À´Ï´Ù. Áø·á¼Ò¿¡¼­´Â Á¤±âÀûÀ¸·Î Áø´Ü °Ë»ç¸¦ ½Ç½ÃÇÏÁö¸¸ º´¿ø°ú ºñ±³ÇÏ¿© °Ë»ç·®ÀÌ ÀûÀ» ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀϺΠŬ¸®´ÐÀº Ÿ¾× ±â¹Ý °Ë»ç¿Í °°Àº ´Ù¸¥ °Ëü äÃë ¹æ¹ýÀ» ¼±ÅÃÇÏ¿© ÀÌ ºÎ¹®ÀÇ ºñÀεΠ½º¿Ò ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. Çмú ¹× ¿¬±¸ ±â°üµµ Áß¿äÇÑ ÃÖÁ¾»ç¿ëÀÚ ºÎ¹®À¸·Î, °úÇÐ ¿¬±¸ ¹× ÀÓ»ó ¿¬±¸ Âü¿©¸¦ ÅëÇØ ºñÀεΠ½º¿Ò ½ÃÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¬±¸±â°üÀº º´¿øÀ̳ª Áø·á¼Ò¸¸Å­ÀÇ ¼öÀÍÀ» âÃâÇÏÁö´Â ¸øÇÏÁö¸¸, ´Ù¾çÇÑ ¿¬±¸¿Í ½ÃÇèÀ¸·Î ÀÎÇØ ºñÀεΠ½º¿Ò¿¡ ´ëÇÑ ¾ÈÁ¤ÀûÀÎ ¼ö¿ä°¡ Àֱ⠶§¹®¿¡ ¾ÈÁ¤ÀûÀÎ ½ÃÀå Á¡À¯À²À» È®º¸Çϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î ¿ä¾ç¿ø, ÀçÅÃÀÇ·á, »ê¾÷½Ã¼³ µîÀ» Æ÷ÇÔÇÑ '±âŸ' Ä«Å×°í¸®´Â º´¿ø, Áø·á¼Ò, ¿¬±¸±â°ü¿¡ ºñÇØ ½ÃÀå Á¡À¯À²ÀÌ ÀÛ½À´Ï´Ù. ½ÃÀå ±Ô¸ð´Â ÀÛÁö¸¸ ÀÌ ºÎ¹®Àº ¿©ÀüÈ÷ Àüü ½ÃÀå ¼öÀÍ¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ºñÀεΠ½º¿Ò°¡ ´Ù¾çÇÑ È¯°æ¿¡¼­ ´ÙÀç´Ù´ÉÇÏ°í Æø³Ð°Ô Àû¿ëµÉ ¼ö ÀÖ´Ù´Â °ÍÀ» ¹Ý¿µÇÕ´Ï´Ù. °á·ÐÀûÀ¸·Î, º´¿øÀº ºñÀεΠ½º¿Ò ½ÃÀå¿¡¼­ °¡Àå ³ôÀº CAGR°ú ¸ÅÃâ¾×À» ±â·ÏÇϸç Áö¹èÀûÀÎ ÃÖÁ¾»ç¿ëÀÚ ºÎ¹®À¸·Î µÎµå·¯Á³½À´Ï´Ù. ÀÌ´Â Áúº´ Áø´Ü¿¡¼­ Áß¿äÇÑ ¿ªÇÒ°ú ½ÃÀå ¼¼ºÐÈ­ Àü¿°º´ ±â°£ µ¿¾È ¼ö¿ä°¡ Áõ°¡Ç߱⠶§¹®ÀÔ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿©ÀüÈ÷ ¼¼°è ¼±µÎÁÖÀÚ

ºÏ¹Ì Áö¿ªÀº 2023-2031³â ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ Áö¿ªÀ¸·Î ºÎ»óÇß½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ÅºÅºÇÑ ÀÇ·á ÀÎÇÁ¶ó, ÷´Ü Áø´Ü ±â¼úÀÇ ±¤¹üÀ§ÇÑ µµÀÔ, Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·ÂÀº ºñÀεΠ¸éºÀ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖÀ¸¸ç, COVID-19ÀÇ ¹ß»ýÀº Áø´Ü Å×½ºÆ®ÀÇ Çʿ伺À» ´õ¿í Áõ°¡½ÃÄÑ ÀÌ Áö¿ªÀÇ ³ôÀº CAGR¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºÏ¹Ì¿¡´Â ¸éºÀ »ý»ê ¹× À¯Åë¿¡ Àû±ØÀûÀ¸·Î Âü¿©ÇÏ´Â ¿©·¯ ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌÀÖ¾î ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾çÀº 2022³â ºñÀεΠ¸éºÀ ½ÃÀå¿¡¼­ °¡Àå ³ôÀº ¸ÅÃâ ºñÁßÀ» Â÷ÁöÇÏ´Â Áö¿ªÀÔ´Ï´Ù. ÀÌ Áö¿ª, ƯÈ÷ Áß±¹°ú Àεµ¿Í °°Àº ±¹°¡¿¡¼­´Â Àα¸°¡ ¸¹±â ¶§¹®¿¡ Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ¸¹¾Æ ºñÀεΠ½º¿ÒÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áúº´ Á¶±â ¹ß°ßÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í È£Èí±â °¨¿°ÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ª¿¡´Â ´Ù¼öÀÇ ÇöÁö Á¦Á¶¾÷ü°¡ Á¸ÀçÇÏ¿© ºñÀεΠ¼¼Ã´¾×ÀÇ ¾ÈÁ¤ÀûÀÎ °ø±ÞÀÌ º¸ÀåµÈ´Ù´Â ÀåÁ¡µµ ÀÖ½À´Ï´Ù. À¯·´°ú ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ µî ´Ù¸¥ Áö¿ªµµ ÀÇ·áºñ Áõ°¡, Áúº´ ºÎ´ã Áõ°¡, ÷´Ü Áø´Ü ±â¼ú µµÀÔÀ¸·Î ÀÎÇØ ºñÀεΠ¼¼Ã´Á¦ ½ÃÀåÀÌ ´«¿¡ ¶ç°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå °æÀïÀº ¿¹Ãø ±â°£ µ¿¾È ´õ¿í Ä¡¿­ÇØÁú °Í

ºñÀεΠ¼¼Ã´¾× ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â Thermo Fisher Scientific, Inc. Biotech Ltd., COPAN Diagnostics, Inc., Miraclean Technology Co. Corporation µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ ±â¾÷µéÀº °­·ÂÇÑ Á¸Àç°¨°ú ½ÃÀå ±â¿©·Î À¯¸íÇÕ´Ï´Ù. ÀÌµé ±â¾÷Àº ¸éºÀ µðÀÚÀÎ ¹× ¼ÒÀçÀÇ Áö¼ÓÀûÀÎ Çõ½Å, ¼¼°è ½ÃÀå ÁøÃâ ¹× À¯Åë È¿À²È­, Àü·«Àû Á¦ÈÞ ¹× Àμö, ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç Áؼö µî ´Ù¾çÇÑ ÁÖ¿ä Àü·«À» äÅÃÇÏ¿© °æÀï·ÂÀ» À¯ÁöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àû±ØÀûÀÎ ¸¶ÄÉÆÃ ¹× ±³À° ÀÌ´Ï¼ÅÆ¼ºê´Â ÀÌµé ±â¾÷ÀÌ ºê·£µå ÀÎÁöµµ¸¦ ³ôÀ̰í Àüü ½ÃÀåÀ» È®´ëÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. Á¦Ç° Áß½ÉÀÇ Àü·« ¿Ü¿¡µµ ÁÖ¿ä ±â¾÷µéÀº Àû±ØÀûÀÎ ¸¶ÄÉÆÃ ¹× ±³À° ÀÌ´Ï¼ÅÆ¼ºê¿¡µµ Àû±Ø ³ª¼­°í ÀÖ½À´Ï´Ù. Áø´Ü °Ë»çÀÇ Á߿伺°ú Áúº´À» Á¶±â¿¡ ¹ß°ßÇÏ´Â µ¥ ÀÖ¾î ºñÀεΠ¼¼Ã´¾×ÀÇ ¿ªÇÒÀ» °­Á¶ÇÏ´Â È«º¸ Ä·ÆäÀÎÀº ºê·£µå ÀÎÁöµµ¸¦ ³ôÀ̰í Àüü ½ÃÀåÀ» È®´ëÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. °æÀï ¿ìÀ§¸¦ À¯ÁöÇϱâ À§ÇØ ÀÌµé ±â¾÷Àº ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀ» ÁؼöÇÏ´Â °ÍÀ» ÃÖ¿ì¼± °úÁ¦·Î »ï°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹À¸·ÎºÎÅÍ ÇÊ¿äÇÑ ÀÎÁõ°ú ½ÂÀÎÀ» ¹Þ±â À§ÇÑ ÅõÀÚ´Â Á¦Ç°ÀÇ ¾ÈÀü°ú ǰÁúÀ» º¸ÀåÇÕ´Ï´Ù. À̴ ȯÀÚ ¾ÈÀü¿¡ ´ëÇÑ ¾à¼ÓÀ» º¸¿©ÁÙ »Ó¸¸ ¾Æ´Ï¶ó ÀÇ·áÁø°ú ÃÖÁ¾»ç¿ëÀÚÀÇ ½Å·Ú¸¦ ±¸ÃàÇÏ´Â µ¥¿¡µµ µµ¿òÀÌ µË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

  • º¸°í¼­ ³»¿ë
    • º¸°í¼­ ¸ñÀû
    • ´ë»óÀÚ
    • ÁÖ¿ä Á¦°ø »óǰ
  • ½ÃÀå ¼¼ºÐÈ­
  • Á¶»ç ¹æ¹ý
    • ´Ü°è¥° - 2Â÷ Á¶»ç
    • ´Ü°è¥± - 1Â÷ Á¶»ç
    • ´Ü°è¥² - Àü¹®°¡ ÆÐ³Î ¸®ºä
    • °¡Á¤
    • ä¿ëÇÑ Á¢±Ù¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ºñÀεΠ½º¿Ò ½ÃÀå : °æÀï ºÐ¼®

  • ÁÖ¿ä º¥´õÀÇ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×
  • º¥´õ°¡ ä¿ëÇÏ´Â Àü·«
  • ÁÖ¿ä »ê¾÷ Àü·«
  • °èÃþ ºÐ¼® : 2022 vs 2031

Á¦4Àå ºñÀεΠ½º¿Ò ½ÃÀå : °Å½ÃÀû ºÐ¼®°ú ½ÃÀå ¿ªÇÐ

  • ¼­·Ð
  • ¼¼°èÀÇ ºñÀεΠ½º¿Ò ½ÃÀå ±Ý¾× 2021-2031
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÁÖ¿ä °úÁ¦
    • ÁÖ¿ä ±âȸ
  • ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇ⠺м®
  • See-Saw ºÐ¼®

Á¦5Àå ºñÀεΠ½º¿Ò ½ÃÀå : À¯Çüº° 2021-2031

  • ½ÃÀå °³¿ä
  • ¼ºÀ塤¸ÅÃ⠺м® : 2022 vs 2031
  • ½ÃÀå ¼¼ºÐÈ­
    • Æû ÆÁ ¸éºÀ
    • ºÎÁ÷Æ÷ ¸éºÀ
    • ±âŸ

Á¦6Àå ºñÀεΠ½º¿Ò ½ÃÀå : ¿ëµµº° 2021-2031

  • ½ÃÀå °³¿ä
  • ¼ºÀ塤¸ÅÃ⠺м® : 2022 vs 2031
  • ½ÃÀå ¼¼ºÐÈ­
    • ÀÎÇ÷翣ÀÚ
    • COVID-19
    • RS ¹ÙÀÌ·¯½º
    • ¹éÀÏÇØ±Õ°¨¿°Áõ
    • MRSA(¸ÞƼ½Ç¸° ³»¼º Ȳ»öÆ÷µµ±¸±Õ)
    • ±âŸ

Á¦7Àå ºñÀεΠ½º¿Ò ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° 2021-2031

  • ½ÃÀå °³¿ä
  • ¼ºÀ塤¸ÅÃ⠺м® : 2022 vs 2031
  • ½ÃÀå ¼¼ºÐÈ­
    • º´¿ø
    • Ŭ¸®´Ð
    • ÇмúÁ¶»ç±â°ü
    • ±âŸ

Á¦8Àå ºÏ¹ÌÀÇ ºñÀεΠ½º¿Ò ½ÃÀå 2021-2031

  • ½ÃÀå °³¿ä
  • ºñÀεΠ½º¿Ò ½ÃÀå : À¯Çüº° 2021-2031
  • ºñÀεΠ½º¿Ò ½ÃÀå : ¿ëµµº° 2021-2031
  • ºñÀεΠ½º¿Ò ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° 2021-2031
  • ºñÀεΠ½º¿Ò ½ÃÀå : Áö¿ªº° 2021-2031
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ±âŸ ºÏ¹Ì

Á¦9Àå ¿µ±¹°ú À¯·´¿¬ÇÕÀÇ ºñÀεΠ½º¿Ò ½ÃÀå 2021-2031

  • ½ÃÀå °³¿ä
  • ºñÀεΠ½º¿Ò ½ÃÀå : À¯Çüº° 2021-2031
  • ºñÀεΠ½º¿Ò ½ÃÀå : ¿ëµµº° 2021-2031
  • ºñÀεΠ½º¿Ò ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° 2021-2031
  • ºñÀεΠ½º¿Ò ½ÃÀå : Áö¿ªº° 2021-2031
    • ¿µ±¹°ú À¯·´¿¬ÇÕ
      • ¿µ±¹
      • µ¶ÀÏ
      • ½ºÆäÀÎ
      • ÀÌÅ»¸®¾Æ
      • ÇÁ¶û½º
      • ±âŸ À¯·´

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ºñÀεΠ½º¿Ò ½ÃÀå 2021-2031

  • ½ÃÀå °³¿ä
  • ºñÀεΠ½º¿Ò ½ÃÀå : À¯Çüº° 2021-2031
  • ºñÀεΠ½º¿Ò ½ÃÀå : ¿ëµµº° 2021-2031
  • ºñÀεΠ½º¿Ò ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° 2021-2031
  • ºñÀεΠ½º¿Ò ½ÃÀå : Áö¿ªº° 2021-2031
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç

Á¦11Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ºñÀεΠ½º¿Ò ½ÃÀå 2021-2031

  • ½ÃÀå °³¿ä
  • ºñÀεΠ½º¿Ò ½ÃÀå : À¯Çüº° 2021-2031
  • ºñÀεΠ½º¿Ò ½ÃÀå : ¿ëµµº° 2021-2031
  • ºñÀεΠ½º¿Ò ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° 2021-2031
  • ºñÀεΠ½º¿Ò ½ÃÀå : Áö¿ªº° 2021-2031
    • ¶óƾ¾Æ¸Þ¸®Ä«
      • ºê¶óÁú
      • ¸ß½ÃÄÚ
      • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«

Á¦12Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ºñÀεΠ½º¿Ò ½ÃÀå 2021-2031

  • ½ÃÀå °³¿ä
  • ºñÀεΠ½º¿Ò ½ÃÀå : À¯Çüº° 2021-2031
  • ºñÀεΠ½º¿Ò ½ÃÀå : ¿ëµµº° 2021-2031
  • ºñÀεΠ½º¿Ò ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° 2021-2031
  • ºñÀεΠ½º¿Ò ½ÃÀå : Áö¿ªº° 2021-2031
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC
      • ¾ÆÇÁ¸®Ä«
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦13Àå ±â¾÷ °³¿ä

  • Thermo Fisher Scientific Inc.
  • Becton Dickinson and Company(formerly C. R. Bard Inc.)
  • Medical Wire & Equipment(MWE)
  • Titan Biotech Ltd.
  • COPAN Diagnostics Inc.
  • Miraclean Technology Co. Ltd.
  • Puritan Medical Products
  • YOCON Biology
  • Trinity Biotech
  • VIRCELL S.L
  • Quidel Corporation
  • ±âŸ ÁÖ¿ä ±â¾÷
ksm 23.10.05

The nasopharyngeal swabs market is expected to grow at a CAGR of 2.5% during the forecast period of 2023 to 2031, driven by the increasing demand for diagnostic testing, particularly during the COVID-19 pandemic. nasopharyngeal swabs are widely used for the collection of respiratory specimens, enabling the detection of infectious diseases, including influenza, respiratory syncytial virus (RSV), and SARS-CoV-2, the virus responsible for COVID-19. One of the key factors contributing to the market's growth is the rising awareness among healthcare professionals and the general public about the importance of early disease detection. nasopharyngeal swabs offer a non-invasive and reliable method to collect respiratory specimens, making them a preferred choice for diagnostic testing. Additionally, the widespread availability of point-of-care testing facilities has further boosted the demand for nasopharyngeal swabs. The market's revenue has witnessed a substantial surge, primarily due to the unprecedented demand for COVID-19 testing during the pandemic. Governments and healthcare organizations across the globe invested heavily in diagnostic testing infrastructure, leading to a surge in the adoption of nasopharyngeal swabs. Moreover, ongoing research and development activities have led to the introduction of innovative swab designs that enhance patient comfort and sample collection efficiency, further driving market growth. However, the market is not without its challenges. Stringent regulatory requirements for medical devices and variations in reimbursement policies across different regions can hinder the growth of nasopharyngeal swabs. Additionally, the emergence of alternative specimen collection methods, such as saliva-based testing, may pose a potential threat to the market's expansion.

Increased Demand for Diagnostic Testing During the COVID-19 Pandemic

The COVID-19 pandemic has been a significant driver of the nasopharyngeal swabs market. The need for widespread diagnostic testing to identify and control the spread of the virus led to a surge in demand for nasopharyngeal swabs. Governments and healthcare organizations worldwide invested heavily in testing infrastructure, contributing to the market's growth. During the pandemic, there were numerous reports of countries experiencing shortages of nasopharyngeal swabs due to unprecedented demand. For instance, in early 2020, the United States faced supply constraints, prompting the government to take measures to increase the production and distribution of swabs to testing facilities. Similar reports emerged from other regions, highlighting the surging demand for nasopharyngeal swabs during the pandemic.

Advancements in Swab Design for Enhanced Patient Comfort and Sample Collection Efficiency

The continuous research and development efforts in the healthcare industry have led to significant improvements in nasopharyngeal swab design. These innovations have focused on increasing patient comfort during sample collection, reducing the invasiveness of the procedure, and improving sample collection efficiency. Published studies in medical journals have reported on various advancements in swab design. These include the development of flexible, softer, and smaller-sized swabs that cause less discomfort to patients during sample collection. Research papers have also highlighted the efficacy of novel swab designs in collecting adequate samples for accurate diagnostic testing, reinforcing the importance of ongoing improvements in swab technology.

Growing Awareness of Early Disease Detection and Point-of-Care Testing Facilities

The increasing awareness among healthcare professionals and the general public about the importance of early disease detection has driven the adoption of nasopharyngeal swabs. Point-of-care testing facilities have become more widely available, making it easier for individuals to get tested quickly and receive prompt results. Public health campaigns, media coverage, and educational initiatives have emphasized the significance of early disease detection. As a result, people are more inclined to undergo diagnostic testing, which often involves nasopharyngeal swabs. Moreover, the establishment of point-of-care testing facilities in clinics, pharmacies, and community centers has made testing more accessible and convenient, further contributing to the demand for nasopharyngeal swabs.

Stringent Regulatory Requirements for Medical Devices

The nasopharyngeal swabs market faces a significant restraint due to the stringent regulatory requirements imposed on medical devices, including swabs. Regulatory authorities across different regions mandate rigorous testing, safety evaluations, and quality control measures before allowing swabs to enter the market. These requirements often lead to longer approval timelines and higher costs for manufacturers. For instance, the U.S. Food and Drug Administration (FDA) requires swab manufacturers to comply with the premarket notification process (510(k)) or obtain premarket approval (PMA) before marketing their products. Similarly, the European Union's CE marking process entails conformity assessments and compliance with essential health and safety requirements for medical devices. These stringent regulatory hurdles can delay product launches and inhibit smaller manufacturers from entering the nasopharyngeal swabs market, impacting overall market growth. As a result, companies must invest significant time and resources to ensure compliance with regulatory guidelines, potentially hindering innovation and restricting market expansion. Published research papers and articles in reputable medical journals discuss the challenges faced by medical device manufacturers in meeting regulatory requirements for nasopharyngeal swabs. These reports detail the complex processes and substantial documentation necessary for obtaining approvals from regulatory authorities. Additionally, case studies highlight instances where companies faced delays and hurdles in introducing nasopharyngeal swabs to the market due to stringent regulatory demands.

Foam-Tipped Swabs to Promise Opportunities During the Forecast Period

Among the different types of nasopharyngeal swabs available in the market, foam-tipped swabs are expected to exhibit the highest CAGR during the forecast period of 2023 to 2031. Foam-tipped swabs are gaining popularity due to their superior performance in sample collection and patient comfort. The soft and flexible foam material minimizes the risk of causing discomfort or injury to the nasal passage during sample collection, making them preferable for both healthcare professionals and patients. Moreover, foam-tipped swabs have demonstrated higher efficiency in collecting an adequate sample for accurate diagnostic testing, leading to increased adoption in various respiratory infections, including COVID-19. As a result, foam-tipped swabs have experienced a significant surge in demand during the COVID-19 pandemic, contributing to their remarkable revenue growth. Non-woven swabs, on the other hand, have shown a comparatively lower CAGR and revenue. Although non-woven swabs are widely used and readily available, they are often perceived to be less comfortable and efficient than foam-tipped swabs. The preference for foam-tipped swabs over non-woven swabs is evident from their higher adoption rates and revenue in the nasopharyngeal swabs market. Lastly, the "Others" category, which includes various types of nasopharyngeal swabs apart from foam-tipped and non-woven, accounts for a smaller portion of the market share. While this segment offers some niche options, it faces challenges in competing with the superior performance and acceptance of foam-tipped swabs. Overall, foam-tipped swabs have emerged as the clear frontrunner in the nasopharyngeal swabs market, experiencing the highest CAGR and generating the highest revenue due to their exceptional efficiency, patient comfort, and increased demand during the COVID-19 pandemic.

Hospitals Remain the Key End Users

Among the various end-user segments in the nasopharyngeal swabs market, hospitals are expected to exhibit the highest CAGR during the forecast period of 2023 to 2031 and revenue generated in 2022. Hospitals are the primary consumers of nasopharyngeal swabs due to their critical role in diagnosing and treating a wide range of respiratory infections. With the surge in infectious diseases like COVID-19, hospitals' demand for nasopharyngeal swabs has skyrocketed, contributing significantly to their high revenue generation. Moreover, hospitals have well-established healthcare infrastructure and laboratories, allowing for efficient and large-scale testing, further boosting the demand for nasopharyngeal swabs. Clinics, although also significant consumers have shown a comparatively lower CAGR and revenue. While clinics regularly perform diagnostic testing, they may have less capacity for testing volume compared to hospitals. Additionally, some clinics may opt for alternative specimen collection methods, such as saliva-based testing, impacting the growth of nasopharyngeal swabs in this segment. Academia & research institutes represent another important end-user segment, contributing to the nasopharyngeal swabs market through their involvement in scientific studies and clinical research. While research institutions may not generate as much revenue as hospitals and clinics, their consistent demand for nasopharyngeal swabs for various studies and trials ensures a stable market share. Lastly, the "Others" category, including settings like nursing homes, home healthcare, and industrial facilities, holds a smaller market share compared to hospitals, clinics, and research institutes. Despite its smaller size, this segment still contributes to the overall market revenue, reflecting the versatility and broad applicability of nasopharyngeal swabs across diverse settings. In conclusion, hospitals stand out as the dominant end-user segment in the nasopharyngeal swabs market, with the highest CAGR and revenue, driven by their crucial role in disease diagnosis and the heightened demand during the COVID-19 pandemic.

APAC remains the Global Leader

North America has emerged as the region with the highest CAGR during the forecast period of 2023 to 2031. The robust healthcare infrastructure, extensive adoption of advanced diagnostic technologies, and proactive government initiatives in the region have fueled the demand for nasopharyngeal swabs. The outbreak of COVID-19 further intensified the need for diagnostic testing, contributing significantly to the region's high CAGR. Additionally, North America houses several key market players actively involved in swab production and distribution, further driving market growth. On the other hand, Asia-Pacific held the distinction of being the region with the highest revenue percentage in the nasopharyngeal swabs market in 2022. The region's large population, especially in countries like China and India, has translated into a substantial demand for diagnostic testing, boosting the adoption of nasopharyngeal swabs. Furthermore, growing awareness of the importance of early disease detection and the increasing prevalence of respiratory infections have driven market growth in Asia-Pacific. The region also benefits from the presence of a significant number of local manufacturers, ensuring a steady supply of nasopharyngeal swabs. Europe and other regions, such as Latin America and the Middle East, have also experienced notable growth in the nasopharyngeal swabs market, driven by increasing healthcare expenditures, rising disease burden, and the adoption of advanced diagnostic technologies.

Market Competition to Intensify during the Forecast Period

Among the top players in the nasopharyngeal swabs market are Thermo Fisher Scientific, Inc., Becton, Dickinson and Company (formerly C. R. Bard, Inc.), Medical Wire & Equipment (MWE), Titan Biotech Ltd., COPAN Diagnostics, Inc., Miraclean Technology Co., Ltd., Puritan Medical Products, YOCON Biology, Trinity Biotech, VIRCELL S.L, and Quidel Corporation. These companies are known for their strong presence and contribution to the market. They employ various key strategies to stay competitive, including continuous innovation in swab designs and materials, global market reach and distribution efficiency, strategic partnerships and acquisitions, and compliance with stringent regulatory requirements. Proactive marketing and educational initiatives also help these companies increase their brand visibility and expand the overall market. In addition to product-focused strategies, top players actively engage in proactive marketing and educational initiatives. Awareness campaigns highlighting the importance of diagnostic testing and the role of nasopharyngeal swabs in early disease detection help increase brand visibility and contribute to overall market expansion. To maintain their competitive advantage, these companies prioritize compliance with stringent regulatory requirements. Investments in obtaining necessary certifications and approvals from regulatory authorities ensure the safety and quality of their products. This not only demonstrates their commitment to patient safety but also builds trust among healthcare professionals and end-users.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofNasopharyngeal Swabs market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Nasopharyngeal Swabs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Type

  • Foam Tipped Swabs
  • Non-woven Swabs
  • Others

Application

  • Influenza
  • COVID-19
  • Respiratory Syncytial Virus
  • Bordetella Pertussis Infection
  • MRSA (Methicillin-resistant Staphylococcus aureus)
  • Others

End-user

  • Hospitals
  • Clinics
  • Academia & Research Institutes
  • Others

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Nasopharyngeal Swabs market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Nasopharyngeal Swabs market?
  • Which is the largest regional market for Nasopharyngeal Swabs market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Nasopharyngeal Swabs market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Nasopharyngeal Swabs market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Nasopharyngeal Swabs Market
  • 2.2. Global Nasopharyngeal Swabs Market, By Type, 2022 (US$ Million)
  • 2.3. Global Nasopharyngeal Swabs Market, By Application, 2022 (US$ Million)
  • 2.4. Global Nasopharyngeal Swabs Market, By End-user, 2022 (US$ Million)
  • 2.5. Global Nasopharyngeal Swabs Market, By Geography, 2022 (US$ Million)
  • 2.6. Attractive Investment Proposition by Geography, 2022

3. Nasopharyngeal Swabs Market: Competitive Analysis

  • 3.1. Market Positioning of Key Nasopharyngeal Swabs Market Vendors
  • 3.2. Strategies Adopted by Nasopharyngeal Swabs Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Nasopharyngeal Swabs Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Nasopharyngeal Swabs Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Foam Tipped Swabs
    • 5.3.2. Non-woven Swabs
    • 5.3.3. Others

6. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Influenza
    • 6.3.2. COVID-19
    • 6.3.3. Respiratory Syncytial Virus
    • 6.3.4. Bordetella Pertussis Infection
    • 6.3.5. MRSA (Methicillin-resistant Staphylococcus aureus)
    • 6.3.6. Others

7. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 7.3. Market Segmentation
    • 7.3.1. Hospitals
    • 7.3.2. Clinics
    • 7.3.3. Academia & Research Institutes
    • 7.3.4. Others

8. North America Nasopharyngeal Swabs Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
  • 8.3. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
  • 8.4. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
  • 8.5.Nasopharyngeal Swabs Market: By Region, 2021-2031, USD (Million)
    • 8.5.1.North America
      • 8.5.1.1. U.S.
        • 8.5.1.1.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 8.5.1.1.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 8.5.1.1.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
      • 8.5.1.2. Canada
        • 8.5.1.2.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 8.5.1.2.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 8.5.1.2.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
      • 8.5.1.3. Rest of North America
        • 8.5.1.3.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 8.5.1.3.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 8.5.1.3.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)

9. UK and European Union Nasopharyngeal Swabs Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
  • 9.3. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
  • 9.4. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
  • 9.5.Nasopharyngeal Swabs Market: By Region, 2021-2031, USD (Million)
    • 9.5.1.UK and European Union
      • 9.5.1.1. UK
        • 9.5.1.1.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.1.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 9.5.1.1.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
      • 9.5.1.2. Germany
        • 9.5.1.2.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.2.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 9.5.1.2.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
      • 9.5.1.3. Spain
        • 9.5.1.3.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.3.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 9.5.1.3.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
      • 9.5.1.4. Italy
        • 9.5.1.4.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.4.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 9.5.1.4.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
      • 9.5.1.5. France
        • 9.5.1.5.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.5.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 9.5.1.5.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
      • 9.5.1.6. Rest of Europe
        • 9.5.1.6.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 9.5.1.6.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 9.5.1.6.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)

10. Asia Pacific Nasopharyngeal Swabs Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
  • 10.3. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
  • 10.4. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
  • 10.5.Nasopharyngeal Swabs Market: By Region, 2021-2031, USD (Million)
    • 10.5.1.Asia Pacific
      • 10.5.1.1. China
        • 10.5.1.1.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.1.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 10.5.1.1.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
      • 10.5.1.2. Japan
        • 10.5.1.2.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.2.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 10.5.1.2.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
      • 10.5.1.3. India
        • 10.5.1.3.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.3.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 10.5.1.3.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
      • 10.5.1.4. Australia
        • 10.5.1.4.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.4.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 10.5.1.4.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
      • 10.5.1.5. South Korea
        • 10.5.1.5.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.5.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 10.5.1.5.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
      • 10.5.1.6. Rest of Asia Pacific
        • 10.5.1.6.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 10.5.1.6.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 10.5.1.6.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)

11. Latin America Nasopharyngeal Swabs Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
  • 11.3. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
  • 11.4. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
  • 11.5.Nasopharyngeal Swabs Market: By Region, 2021-2031, USD (Million)
    • 11.5.1.Latin America
      • 11.5.1.1. Brazil
        • 11.5.1.1.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 11.5.1.1.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 11.5.1.1.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
      • 11.5.1.2. Mexico
        • 11.5.1.2.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 11.5.1.2.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 11.5.1.2.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
      • 11.5.1.3. Rest of Latin America
        • 11.5.1.3.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 11.5.1.3.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 11.5.1.3.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)

12. Middle East and Africa Nasopharyngeal Swabs Market, 2021-2031, USD (Million)

  • 12.1. Market Overview
  • 12.2. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
  • 12.3. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
  • 12.4. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
  • 12.5.Nasopharyngeal Swabs Market: By Region, 2021-2031, USD (Million)
    • 12.5.1.Middle East and Africa
      • 12.5.1.1. GCC
        • 12.5.1.1.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 12.5.1.1.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 12.5.1.1.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
      • 12.5.1.2. Africa
        • 12.5.1.2.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 12.5.1.2.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 12.5.1.2.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)
      • 12.5.1.3. Rest of Middle East and Africa
        • 12.5.1.3.1. Nasopharyngeal Swabs Market: By Type, 2021-2031, USD (Million)
        • 12.5.1.3.2. Nasopharyngeal Swabs Market: By Application, 2021-2031, USD (Million)
        • 12.5.1.3.3. Nasopharyngeal Swabs Market: By End-user, 2021-2031, USD (Million)

13. Company Profile

  • 13.1. Thermo Fisher Scientific, Inc.
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Portfolio
    • 13.1.4. Strategic Initiatives
  • 13.2. Becton, Dickinson and Company (formerly C. R. Bard, Inc.)
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Portfolio
    • 13.2.4. Strategic Initiatives
  • 13.3. Medical Wire & Equipment (MWE)
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Portfolio
    • 13.3.4. Strategic Initiatives
  • 13.4. Titan Biotech Ltd.
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Portfolio
    • 13.4.4. Strategic Initiatives
  • 13.5. COPAN Diagnostics, Inc.
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Portfolio
    • 13.5.4. Strategic Initiatives
  • 13.6. Miraclean Technology Co., Ltd.
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Portfolio
    • 13.6.4. Strategic Initiatives
  • 13.7. Puritan Medical Products
    • 13.7.1. Company Overview
    • 13.7.2. Financial Performance
    • 13.7.3. Product Portfolio
    • 13.7.4. Strategic Initiatives
  • 13.8. YOCON Biology
    • 13.8.1. Company Overview
    • 13.8.2. Financial Performance
    • 13.8.3. Product Portfolio
    • 13.8.4. Strategic Initiatives
  • 13.9. Trinity Biotech
    • 13.9.1. Company Overview
    • 13.9.2. Financial Performance
    • 13.9.3. Product Portfolio
    • 13.9.4. Strategic Initiatives
  • 13.10. VIRCELL S.L
    • 13.10.1. Company Overview
    • 13.10.2. Financial Performance
    • 13.10.3. Product Portfolio
    • 13.10.4. Strategic Initiatives
  • 13.11. Quidel Corporation
    • 13.11.1. Company Overview
    • 13.11.2. Financial Performance
    • 13.11.3. Product Portfolio
    • 13.11.4. Strategic Initiatives
  • 13.12. Other Notable Players
    • 13.12.1. Company Overview
    • 13.12.2. Financial Performance
    • 13.12.3. Product Portfolio
    • 13.12.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦